

TTKH:SEC:MA:257:22 December 06, 2022

BSE Limited PhirozeJeejeebhoy Towers Dalal Street Mumbai 400 001 National Stock Exchange of India Limited Exchange Plaza BandraKurla Complex, Bandra East Mumbai 400 051

Scrip Code: 507747 Scrip Code: TTKHLTCARE

Dear Sirs,

Re: Update on Sale / Transfer of Human Pharma Division (Undertaking)

of the Company - Receipt of balance 26% consideration.

This is with further reference to our earlier communication dated 9th May, 2022, on the above subject.

As already informed, in terms of the Business Transfer Agreement dated 21st March, 2022, the Company received from M/s. BSV Pharma Pvt. Ltd. a sum of Rs.593.11 crores on 9th May, 2022 (being 74% of the consideration after the preliminary adjustments for working capital) in cash and the balance Rs.208.39 crores being the 26% of consideration was received in the form of Equity Shares (20,83,90,260 Equity Shares of Rs.10/- each) allotted in our favour in the said M/s. BSV Pharma Pvt. Ltd., on 9th May, 2022.

The Agreement also provided for the purchase of the aforesaid 26% Equity Shares held by us in M/s. BSV Pharma Pvt. Ltd., by M/s Bharat Serums and Vaccines Limited or its nominees, after they obtain necessary regulatory clearances.

Consequent upon the receipt of necessary regulatory clearances by M/s Bharat Serums and Vaccines Limited, they have today remitted a sum of Rs.208.39 crores towards the consideration for the purchase of the said 20,83,90,260 Equity Shares of Rs.10/- each held by us in M/s BSV Pharma Pvt. Ltd., and the said shares are being transferred to them.

Kindly take the above information on record.

Thanking you,

Yours faithfully

For TTK Healthcare Limited

(S KALYANARAMAN)

Wholetime Director & Secretary